Dr. Zastrozhin made significant and widely recognized contributions to the study of pharmacoepidemiology and the development of personalized medicine at the international level, including the study of the complex mutual influence of omics biomarkers (pharmacogenomic, pharmacometabolomic, pharmacotranscriptomic), as well as their influence on individual drug responses. With more than a decade of academic, clinical, and research experience in these fields, he has exceptional publications and citations record (>80 articles, many first-co-first authored, ~8,000 citations, >80% independent). His work has had a substantial and enduring impact on personalized medicine.
Pharmacogenomics (PGx) Showcase:
The University of California, San Francisco is a public land-grant research university in San Francisco, California. It is part of the University of California system and is dedicated entirely to health science and life science.
Omics technologies to improve the quality of therapy
The relationship of microRNAs, activity of isoenzymes of biotransformation, pharmacogenetics and pharmacokinetics, efficacy and safety of drugs.